This molecule has been studied in Phase I trials in patients with EGFR-mutated NSCLC who developed resistance to EGFR-TKI therapy, with an ORR of 39% and mPFS of 8.2 months74. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.